Alzheimer's Antibody Fails to Slow Memory Decline
Adults with mild Alzheimer's-related memory problems saw plaque drop in a trial, but the drug did not slow their decline.
Updated on Nov. 7, 2026 in Alzheimer’s
Acumen Pharmaceuticals has stopped commercial development of sabirnetug, an Alzheimer's antibody, after it failed a Phase 2 trial announced October 30. The drug showed no effect on clinical decline in people with mild cognitive impairment or mild dementia due to Alzheimer's disease, though it did lower plaque in the brain.
Why it matters
For the millions of people worldwide living with or at risk of Alzheimer's, the result shows that reducing amyloid plaque alone does not necessarily slow cognitive and functional decline. Acumen started the trial because Phase 1 data showed plaque reduction and target engagement, so the failure is a useful reminder of how difficult it is to translate biomarker changes into clinical benefit.
This was a Phase 2 randomized, placebo-controlled trial with 542 people who had mild cognitive impairment or mild dementia due to Alzheimer's disease. Plaque was lowered, but neither dose slowed clinical decline, and about 10 percent of treated participants developed ARIA-E.
The players
Acumen Pharmaceuticals
A biotechnology company developing treatments for Alzheimer's disease that is focused on amyloid-targeting antibodies.
JCR Pharmaceuticals
A Japanese drugmaker whose brain shuttle technology is being used by Acumen to develop a new version of sabirnetug.
The details
Sabirnetug was designed to bind amyloid-beta oligomers, which are small clumps of the protein thought to be particularly harmful, with 650-fold greater affinity than the single-molecule form. Participants received 18 monthly infusions of placebo, 35 mg/kg, or 50 mg/kg sabirnetug. Plaque reduction became significant only after about nine months on the drug, yet the lower amyloid load did not translate into slower decline on the integrated rating scale.
Timeline
• February 2024: The Phase 2 Altitude-AD trial began.
• October 30: Acumen announced top-line results and halted commercial development.
• August 2026: Data on the brain shuttle version were presented at an Alzheimer's Association conference.
Health Landscape
Sabirnetug's failure adds to a body of anti-amyloid antibody trials where plaque reduction has not reliably produced slower cognitive decline. The result sharpens the question of which biomarkers and patient stages will actually predict clinical benefit.
If you or a family member is living with memory concerns, this result is a reminder that lowering amyloid on a scan does not automatically mean a slower decline in daily function. It is worth discussing with your doctor which current evidence-based options and clinical trials may be appropriate.
The takeaway
Reducing amyloid plaque is not the same as slowing decline, and researchers are still working out which measures matter most. If you have questions about memory or Alzheimer's treatment options, bring them to your physician.
What happens next
Acumen is still evaluating a brain shuttle version of sabirnetug with JCR Pharmaceuticals, and data on that version were presented at an Alzheimer's Association conference in August 2026.
Further reading
For broader context on treatment research, see the Alzheimer's section.
Source note: This article includes information reported by Alzheimer Research Forum.
